CN116549612A - 一种含植物干细胞因子的抑菌组合物及其制备方法 - Google Patents
一种含植物干细胞因子的抑菌组合物及其制备方法 Download PDFInfo
- Publication number
- CN116549612A CN116549612A CN202310535092.2A CN202310535092A CN116549612A CN 116549612 A CN116549612 A CN 116549612A CN 202310535092 A CN202310535092 A CN 202310535092A CN 116549612 A CN116549612 A CN 116549612A
- Authority
- CN
- China
- Prior art keywords
- stem cell
- plant stem
- cell factor
- extract
- ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 76
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 241000196324 Embryophyta Species 0.000 title claims abstract description 37
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000000419 plant extract Substances 0.000 claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 9
- 241000894006 Bacteria Species 0.000 claims abstract description 7
- 239000000284 extract Substances 0.000 claims description 54
- 238000001556 precipitation Methods 0.000 claims description 25
- 230000003385 bacteriostatic effect Effects 0.000 claims description 23
- 239000000126 substance Substances 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 15
- 239000003242 anti bacterial agent Substances 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 241000628997 Flos Species 0.000 claims description 12
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims description 12
- 229940093265 berberine Drugs 0.000 claims description 12
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims description 12
- 239000000758 substrate Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 230000000975 bioactive effect Effects 0.000 claims description 11
- NJYVDFDTLLZVMG-UHFFFAOYSA-N echinacoside Natural products CC1OC(OC2C(O)C(OCCc3ccc(O)c(O)c3)OC(COC4OC(CO)C(O)C(O)C4O)C2OC(=O)C=Cc5cc(O)cc(O)c5)C(O)C(O)C1O NJYVDFDTLLZVMG-UHFFFAOYSA-N 0.000 claims description 11
- FSBUXLDOLNLABB-ISAKITKMSA-N echinacoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FSBUXLDOLNLABB-ISAKITKMSA-N 0.000 claims description 11
- 229930182470 glycoside Natural products 0.000 claims description 10
- 150000002338 glycosides Chemical class 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 241000405414 Rehmannia Species 0.000 claims description 9
- 238000004821 distillation Methods 0.000 claims description 9
- 241001570521 Lonicera periclymenum Species 0.000 claims description 8
- 239000003906 humectant Substances 0.000 claims description 8
- 239000004599 antimicrobial Substances 0.000 claims description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 claims description 6
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 230000004071 biological effect Effects 0.000 claims description 6
- 239000013522 chelant Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 235000008434 ginseng Nutrition 0.000 claims description 6
- 239000013049 sediment Substances 0.000 claims description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 6
- 230000000259 anti-tumor effect Effects 0.000 claims description 5
- 230000000840 anti-viral effect Effects 0.000 claims description 5
- 239000004909 Moisturizer Substances 0.000 claims description 4
- 239000012752 auxiliary agent Substances 0.000 claims description 4
- 230000001333 moisturizer Effects 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 206010064147 Gastrointestinal inflammation Diseases 0.000 claims description 3
- 206010061459 Gastrointestinal ulcer Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 244000173853 Sanguisorba officinalis Species 0.000 claims description 3
- 235000008282 Sanguisorba officinalis Nutrition 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 230000003467 diminishing effect Effects 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 229940089161 ginsenoside Drugs 0.000 claims description 3
- 229930182494 ginsenoside Natural products 0.000 claims description 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 244000000074 intestinal pathogen Species 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 3
- 244000052769 pathogen Species 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 238000003892 spreading Methods 0.000 claims description 3
- 230000007480 spreading Effects 0.000 claims description 3
- 229940032094 squalane Drugs 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 231100000397 ulcer Toxicity 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 244000131316 Panax pseudoginseng Species 0.000 claims 17
- 235000007516 Chrysanthemum Nutrition 0.000 claims 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims 1
- 244000133098 Echinacea angustifolia Species 0.000 claims 1
- 244000303040 Glycyrrhiza glabra Species 0.000 claims 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims 1
- 241000245240 Lonicera Species 0.000 claims 1
- 240000000249 Morus alba Species 0.000 claims 1
- 235000008708 Morus alba Nutrition 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 240000002948 Ophiopogon intermedius Species 0.000 claims 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims 1
- 235000006751 Platycodon Nutrition 0.000 claims 1
- 244000274050 Platycodon grandiflorum Species 0.000 claims 1
- 244000197580 Poria cocos Species 0.000 claims 1
- 235000008599 Poria cocos Nutrition 0.000 claims 1
- 235000014134 echinacea Nutrition 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 claims 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims 1
- 235000011477 liquorice Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims 1
- 229930189914 platycodon Natural products 0.000 claims 1
- 230000003020 moisturizing effect Effects 0.000 abstract description 5
- 208000035143 Bacterial infection Diseases 0.000 abstract description 3
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 230000001954 sterilising effect Effects 0.000 abstract 1
- 241000208340 Araliaceae Species 0.000 description 37
- 239000002075 main ingredient Substances 0.000 description 6
- 244000167230 Lonicera japonica Species 0.000 description 4
- 235000017617 Lonicera japonica Nutrition 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 2
- 241000050051 Chelone glabra Species 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 241000180649 Panax notoginseng Species 0.000 description 2
- 235000003143 Panax notoginseng Nutrition 0.000 description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 2
- 241000219784 Sophora Species 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229940088623 biologically active substance Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- SQFSKOYWJBQGKQ-UHFFFAOYSA-N kaempferide Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 SQFSKOYWJBQGKQ-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 206010061126 Escherichia infection Diseases 0.000 description 1
- 208000035109 Pneumococcal Infections Diseases 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 208000020612 escherichia coli infection Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Insects & Arthropods (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Animal Husbandry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于含植物干细胞因子的抑菌组合物制备技术领域,且公开了一种含植物干细胞因子的抑菌组合物及其制备方法,所述含植物干细胞因子的抑菌组合物的成分包括有人参植物干细胞因子、一种或多种抗菌剂、正电荷化的植物提取物/衍生物、天然保湿剂、生物活性物质和一种或多种辅助材料。该组合物可用于杀菌并抑制多种细菌的生长,同时具有保湿、修复和抗氧化等多种功效,同时可以治疗各种细菌感染,由于该组合物采用天然植物提取物/衍生物制备,因此具有较好的生物相容性和安全性。
Description
技术领域
本发明属于含植物干细胞因子的抑菌组合物制备技术领域,具体为一种含植物干细胞因子的抑菌组合物及其制备方法。
背景技术
干细胞因子是一类可以刺激细胞增殖和分化的信号蛋白,同时具备促进细胞再生和修复的功能,使其在医学和美容领域有着广泛的应用前景,现在医疗和卫生领域中细菌感染是一种常见且严重的问题,目前市面上虽然有许多抗生素可以用于治疗细菌感染,但针对于部分细菌抗药性较强,这些抗生素的抑菌效果也会随之逐渐减弱,同时传统的抗生素治疗,针对性较强,可能会导致抗生素耐药性和其他副作用,并且在治疗保湿效果较差,从而急需要一种具有广谱抑菌作用,并且能够同时达到多种修复和保湿效果的天然抑菌剂具有重要的临床应用价值,因此提出一种含植物干细胞因子的抑菌组合物及其制备方法。
发明内容
本发明的目的在于提供一种含植物干细胞因子的抑菌组合物及其制备方法,以解决上述背景技术中提出的问题。
为了实现上述目的,本发明提供如下技术方案:
一种含植物干细胞因子的抑菌组合物,所述含植物干细胞因子的抑菌组合物包含以下成分:
(1)人参植物干细胞因子;
(2)一种或多种抗菌剂;
(3)正电荷化的植物提取物/衍生物;
(4)天然保湿剂;
(5)生物活性物质;
(6) 一种或多种辅助材料。
优选地,所述人参植物干细胞因子为人参皂苷,将人参经过提取、纯化和干燥后的人参植物干细胞因子,具有抗菌、抗病毒、抗肿瘤的生物活性。
优选地,所述抗菌剂可以选择组成黄连素、三七素、金银花素、茯苓多糖、熟地黄苷、桑白皮素、和紫锥菊苷中的一种或多种,
(1)黄连素为提取自黄连中的主要成分;
(2)三七素为提取自三七中的主要成分:
(3)金银花素为提取自金银花中的主要成分;
(4)茯苓多糖为提取自茯苓中的主要成分;
(5)熟地黄苷为提取自熟地黄中的主要成分;
(6)桑白皮素为提取自桑白皮中的主要成分:
(7)紫锥菊苷为提取自紫锥菊中的主要成分,
所述黄连素、三七素、金银花素、茯苓多糖、熟地黄苷、桑白皮素、和紫锥菊苷均具有广谱抗菌、抗病毒、抗肿瘤的生物活性,所述黄连素和金银花素还针对肠道病原菌和呼吸道病原菌具有较好的抑制作用。
优选地,所述天然保湿剂为玻尿酸、甘油、天然植物精华、角鲨烷等中的一种或多种,所述生物活性物质为维生素E、胶原蛋白、蜂蜜等中的一种或多种。
优选地,所述辅助材料为一种或多种从以下组成中选择的物质:
(1)缓冲剂的成分为黄芩提取物、苦参提取物和白芍提取物混合,具有清热解毒、消炎镇痛、抗菌抗病毒的作用,能够有效地缓解胃肠道炎症和溃疡等症状;
(2)助剂包括有多聚体、溶剂;
(3)其他辅助材料包括有抗氧化剂、防腐剂。
优选地,所述植物提取物/衍生物包括麦冬,甘草,桔梗、桑叶、菊花、乌梅、双花中的一种或多种植物的提取物/衍生物,植物提取物/衍生物的正电荷化通过以下方式实现:将植物提取物/衍生物在等离子体反应器内进行等离子化学反应,然后铺在带负电的晶片基材上以吸引正电荷与植物提取物/衍生物螯合,并通过反方向设置的带正电晶片基材将负电荷吸走。
一种制备上述含植物干细胞因子的抑菌组合物的制备方法,包括以下步骤:
S1:先取人参,并加水,在温度65°C-75°C、真空度0.06Mpa-0.07Mpa的条件下蒸馏提取,使得馏出液的体积为加水量的一半时,停止蒸馏,并进行收集,此时可以获得第一馏出液;
S2:在剩余的料液中继续加水,然后在温度70°C-80°C、真空度0.05Mpa-0.06Mpa的条件下蒸馏提取,当馏出液的体积为加水量的一半时,停止蒸馏,并进行收集,此时可以获得第二馏出液;
S3:将S1中得到的第一馏出液和第二馏出液混合,此时可以获得含有人参植物干细胞因子的提取液;
S4:采用乙醇分级沉淀法对含有人参植物干细胞因子的提取物进行纯化,并得到图1,沉淀量分别为:1.68%、1.37%、3.47%、41.70%、15.26%、7.25%、4.71%、3.13%,通过 HPLC检测沉淀Ⅰ至沉淀8,由检测结果可知随乙醇添加量的增多,沉淀组分的主峰所占比例逐步提高,由沉淀1的72.3%上升为沉淀8的96.6%。沉淀5至沉淀8纯度均在96%以上,且分子质量均在1800D左右,可以认为是同种物质,然后合并,此时可以获得含人参植物干细胞因子的纯化物;
S5:将含人参植物干细胞因子的纯化物与一种或多种抗菌剂混合,随后可以获得含人参植物干细胞因子的初级混合物;
S6:制作麦冬,甘草,桔梗、桑叶、菊花、乌梅、双花中的一种或多种植物的提取物/衍生物,将植物提取物/衍生物在等离子体反应器内处理0-24小时进行等离子化学反应,然后铺在带负电的晶片基材上以吸引正电荷与植物提取物/衍生物螯合,并通过反方向设置的带正电晶片基材将负电荷吸走,获得正电荷化的植物提取物/衍生物,将正电荷化的植物提取物/衍生物与含人参植物干细胞因子的初级混合物混合,获得含人参植物干细胞因子的二级混合物;
S7:将含人参植物干细胞因子的二级混合物与一种或多种天然保湿剂和生物活性物质混合,随后可以获得含人参植物干细胞因子的三级混合物;
S8:向含人参植物干细胞因子的三级混合物内部加入一种或多种辅助材料,混合后,制备成含有人参植物干细胞因子的抑菌组合物。
优选地,所述抑菌组合物的制备方法S5、S6和S8步骤中:所述抗菌剂的总质量百分比为0.1%至10%;所述正电荷化的植物提取物/衍生物的浓度范围为0.0001mg / ml-100mg/ ml,所述辅助材料的总质量百分比为90%至99.9%。
优选地,所述抑菌组合物的制备方法S5和S7步骤中混合的抗菌剂、天然保湿剂和生物活性物质的配比比例为3:1:1。
优选地,所述抑菌组合物的制备方法S8步骤中含植物干细胞因子的抑菌组合物可制成0.1克至10克的口服药物、0.5克至5克的外用药物、0.05克至1克的注射剂。
本发明的有益效果如下:
1、本发明通过提取人参植物干细胞因子,然后纯化提取物,获得含有纯化的人参植物干细胞因子的纯化物,随后将纯化的人参植物干细胞因子与一种或多种抗菌剂混合,获得初级混合物,之后将初级混合物与正电荷化的植物提取物/衍生物混合获得二级混合物,之后将二级混合物与一种或多种天然保湿剂和生物活性物质混合,获得含人参植物干细胞因子的三级混合物,最终向三级混合物的内部加入一种或多种辅助材料,从而可以制备成含有人参植物干细胞因子的抑菌组合物,其中正电荷化的植物提取物/衍生物可以使该抑菌组合物含有稳定的正电荷,由于病毒表面具有带负电荷的区域,因此使用时抑菌组合物中的正电荷可以吸附病毒,进而可以击穿病毒包膜并破坏病毒结构,再结合该抑菌组合物中的抗菌剂,从而可以达到杀菌并抑制多种细菌的生长的效果,同时具有保湿、修复和抗氧化等多种功效,同时可以治疗各种细菌感染,由于该组合物采用天然植物提取物/衍生物制备,因此具有较好的生物相容性和安全性。
附图说明
图1为本发明植物干细胞提取物的分级沉淀柱状图。
实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例
本发明实施例提供了一种含植物干细胞因子的抑菌组合物,含植物干细胞因子的抑菌组合物包含以下成分:
(1)人参植物干细胞因子;
(2)一种或多种抗菌剂;
(3)正电荷化的植物提取物/衍生物;
(4)天然保湿剂;
(5)生物活性物质;
(6) 一种或多种辅助材料。
在一个实施例中,人参植物干细胞因子为人参皂苷,将人参经过提取、纯化和干燥后的人参植物干细胞因子,具有抗菌、抗病毒、抗肿瘤的生物活性。
在一个实施例中,抗菌剂可以选择组成黄连素、三七素、金银花素、茯苓多糖、熟地黄苷、桑白皮素、和紫锥菊苷中的一种或多种,
(1)黄连素为提取自黄连中的主要成分;
(2)三七素为提取自三七中的主要成分:
(3)金银花素为提取自金银花中的主要成分;
(4)茯苓多糖为提取自茯苓中的主要成分;
(5)熟地黄苷为提取自熟地黄中的主要成分;
(6)桑白皮素为提取自桑白皮中的主要成分:
(7)紫锥菊苷为提取自紫锥菊中的主要成分,
黄连素、三七素、金银花素、茯苓多糖、熟地黄苷、桑白皮素、和紫锥菊苷均具有广谱抗菌、抗病毒、抗肿瘤的生物活性,黄连素和金银花素还针对肠道病原菌和呼吸道病原菌具有较好的抑制作用。
在一个实施例中,天然保湿剂为玻尿酸、甘油、天然植物精华、角鲨烷等中的一种或多种,生物活性物质为维生素E、胶原蛋白、蜂蜜等中的一种或多种。
在一个实施例中,辅助材料为一种或多种从以下组成中选择的物质:
(1)缓冲剂的成分为黄芩提取物、苦参提取物和白芍提取物混合,具有清热解毒、消炎镇痛、抗菌抗病毒的作用,能够有效地缓解胃肠道炎症和溃疡等症状;
(2)助剂包括有多聚体、溶剂;
(3)其他辅助材料包括有抗氧化剂、防腐剂。
在一个实施例中,所述植物提取物/衍生物包括麦冬,甘草,桔梗、桑叶、菊花、乌梅、双花中的一种或多种植物的提取物/衍生物,植物提取物/衍生物的正电荷化通过以下方式实现:将植物提取物/衍生物在等离子体反应器内进行等离子化学反应,然后铺在带负电的晶片基材上以吸引正电荷与植物提取物/衍生物螯合,并通过反方向设置的带正电晶片基材将负电荷吸走。
实施例2:一种制备上述含植物干细胞因子的抑菌组合物的制备方法,包括以下步骤:
S1:先取人参,并加水,在温度65°C-75°C、真空度0.06Mpa-0.07Mpa的条件下蒸馏提取,使得馏出液的体积为加水量的一半时,停止蒸馏,并进行收集,此时可以获得第一馏出液;
S2:在剩余的料液中继续加水,然后在温度70°C-80°C、真空度0.05Mpa-0.06Mpa的条件下蒸馏提取,当馏出液的体积为加水量的一半时,停止蒸馏,并进行收集,此时可以获得第二馏出液;
S3:将S1中得到的第一馏出液和第二馏出液混合,此时可以获得含有人参植物干细胞因子的提取液;
S4:采用乙醇分级沉淀法对含有人参植物干细胞因子的提取物进行纯化,并得到图1,沉淀量分别为:1.68%、1.37%、3.47%、41.70%、15.26%、7.25%、4.71%、3.13%,通过 HPLC检测沉淀Ⅰ至沉淀8,由检测结果可知随乙醇添加量的增多,沉淀组分的主峰所占比例逐步提高,由沉淀1的72.3%上升为沉淀8的96.6%。沉淀5至沉淀8纯度均在96%以上,且分子质量均在1800D左右,可以认为是同种物质,然后合并,此时可以获得含人参植物干细胞因子的纯化物;
S5:将含人参植物干细胞因子的纯化物与一种或多种抗菌剂混合,随后可以获得含人参植物干细胞因子的初级混合物;
S6:制作麦冬,甘草,桔梗、桑叶、菊花、乌梅、双花中的一种或多种植物的提取物/衍生物,将植物提取物/衍生物在等离子体反应器内处理0-24小时进行等离子化学反应,然后铺在带负电的晶片基材上以吸引正电荷与植物提取物/衍生物螯合,并通过反方向设置的带正电晶片基材将负电荷吸走,获得正电荷化的植物提取物/衍生物,将正电荷化的植物提取物/衍生物与含人参植物干细胞因子的初级混合物混合,获得含人参植物干细胞因子的二级混合物;
S7:将含人参植物干细胞因子的二级混合物与一种或多种天然保湿剂和生物活性物质混合,随后可以获得含人参植物干细胞因子的三级混合物;
S8:向含人参植物干细胞因子的三级混合物内部加入一种或多种辅助材料,混合后,制备成含有人参植物干细胞因子的抑菌组合物。
在一个实施例中,所述抑菌组合物的制备方法S5、S6和S8步骤中:所述抗菌剂的总质量百分比为0.1%至10%;所述正电荷化的植物提取物/衍生物的浓度范围为0.0001mg /ml-100mg / ml,所述辅助材料的总质量百分比为90%至99.9%。
在一个实施例中,抑菌组合物的制备方法S5和S7步骤中混合的抗菌剂、天然保湿剂和生物活性物质的配比比例为3:1:1。
在一个实施例中,抑菌组合物的制备方法S8步骤中含植物干细胞因子的抑菌组合物可制成0.1克至10克的口服药物、0.5克至5克的外用药物、0.05克至1克的注射剂。
在一个实施例中,抑菌组合物的制备方法S8步骤中含植物干细胞因子的抑菌组合物可用于治疗各种细菌感染,包括但不限于肺炎球菌感染、大肠杆菌感染、金黄色葡萄球菌感染、链球菌感染。
需要说明的是,在本文中,诸如第一和第二等之类的关系术语仅仅用来将一个实体或者操作与另一个实体或操作区分开来,而不一定要求或者暗示这些实体或操作之间存在任何这种实际的关系或者顺序。而且,术语“包括”、“包含”或者其任何其他变体意在涵盖非排他性的包含,从而使得包括一系列要素的过程、方法、物品或者设备不仅包括那些要素,而且还包括没有明确列出的其他要素,或者是还包括为这种过程、方法、物品或者设备所固有的要素。
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。
Claims (10)
1.一种含植物干细胞因子的抑菌组合物,其特征在于:所述含植物干细胞因子的抑菌组合物的成分包括有人参植物干细胞因子、一种或多种抗菌剂、正电荷化的植物提取物/衍生物、天然保湿剂、生物活性物质和一种或多种辅助材料。
2.根据权利要求1所述的一种含植物干细胞因子的抑菌组合物,其特征在于:所述人参植物干细胞因子为人参皂苷,将人参经过提取、纯化和干燥后的人参植物干细胞因子,具有抗菌、抗病毒、抗肿瘤的生物活性。
3.根据权利要求1所述的一种含植物干细胞因子的抑菌组合物,其特征在于:所述抗菌剂可以选择组成黄连素、三七素、金银花素、茯苓多糖、熟地黄苷、桑白皮素、和紫锥菊苷中的一种或多种,
所述黄连素为提取自黄连中的主要成分;
所述三七素为提取自三七中的主要成分:
所述金银花素为提取自金银花中的主要成分;
所述茯苓多糖为提取自茯苓中的主要成分;
所述熟地黄苷为提取自熟地黄中的主要成分;
所述桑白皮素为提取自桑白皮中的主要成分:
所述紫锥菊苷为提取自紫锥菊中的主要成分,
所述黄连素、三七素、金银花素、茯苓多糖、熟地黄苷、桑白皮素、和紫锥菊苷均具有广谱抗菌、抗病毒、抗肿瘤的生物活性,所述黄连素和金银花素还针对肠道病原菌和呼吸道病原菌具有较好的抑制作用。
4.根据权利要求1所述的一种含植物干细胞因子的抑菌组合物,其特征在于:所述天然保湿剂为玻尿酸、甘油、天然植物精华、角鲨烷等中的一种或多种,所述生物活性物质为维生素E、胶原蛋白、蜂蜜等中的一种或多种。
5.根据权利要求1所述的一种含植物干细胞因子的抑菌组合物,其特征在于:所述辅助材料可以选择组成缓冲剂和助剂中的一种或多种,
所述缓冲剂的成分为黄芩提取物、苦参提取物和白芍提取物混合,具有清热解毒、消炎镇痛、抗菌抗病毒的作用,能够有效地缓解胃肠道炎症和溃疡等症状;
所述助剂包括多聚体和溶剂。
6.根据权利要求1所述的一种含植物干细胞因子的抑菌组合物,其特征在于:所述植物提取物/衍生物包括麦冬,甘草,桔梗、桑叶、菊花、乌梅、双花中的一种或多种植物的提取物/衍生物,植物提取物/衍生物的正电荷化通过以下方式实现:将植物提取物/衍生物在等离子体反应器内进行等离子化学反应,然后铺在带负电的晶片基材上以吸引正电荷与植物提取物/衍生物螯合,并通过反方向设置的带正电晶片基材将负电荷吸走。
7.一种制备如权利要求1-6所述的含植物干细胞因子的抑菌组合物的制备方法,其特征在于:
S1:先取人参,并加水,在温度65°C-75°C、真空度0.06Mpa-0.07Mpa的条件下蒸馏提取,使得馏出液的体积为加水量的一半时,停止蒸馏,并进行收集,此时可以获得第一馏出液;
S2:在剩余的料液中继续加水,然后在温度70°C-80°C、真空度0.05Mpa-0.06Mpa的条件下蒸馏提取,当馏出液的体积为加水量的一半时,停止蒸馏,并进行收集,此时可以获得第二馏出液;
S3:将S1中得到的第一馏出液和第二馏出液混合,此时可以获得含有人参植物干细胞因子的提取液;
S4:采用乙醇分级沉淀法对含有人参植物干细胞因子的提取物进行纯化,并得到图1,沉淀量分别为:1.68%、1.37%、3.47%、41.70%、15.26%、7.25%、4.71%、3.13%,通过 HPLC检测沉淀Ⅰ至沉淀8,由检测结果可知随乙醇添加量的增多,沉淀组分的主峰所占比例逐步提高,由沉淀1的72.3%上升为沉淀8的96.6%。沉淀5至沉淀8纯度均在96%以上,且分子质量均在1800D左右,可以认为是同种物质,然后合并,此时可以获得含人参植物干细胞因子的纯化物;
S5:将含人参植物干细胞因子的纯化物与一种或多种抗菌剂混合,随后可以获得含人参植物干细胞因子的初级混合物;
S6:制作麦冬,甘草,桔梗、桑叶、菊花、乌梅、双花中的一种或多种植物的提取物/衍生物,将植物提取物/衍生物在等离子体反应器内处理0-24小时进行等离子化学反应,然后铺在带负电的晶片基材上以吸引正电荷与植物提取物/衍生物螯合,并通过反方向设置的带正电晶片基材将负电荷吸走,获得正电荷化的植物提取物/衍生物,将正电荷化的植物提取物/衍生物与含人参植物干细胞因子的初级混合物混合,获得含人参植物干细胞因子的二级混合物;
S7:将含人参植物干细胞因子的二级混合物与一种或多种天然保湿剂和生物活性物质混合,随后可以获得含人参植物干细胞因子的三级混合物;
S8:向含人参植物干细胞因子的三级混合物内部加入一种或多种辅助材料,混合后,制备成含有人参植物干细胞因子的抑菌组合物。
8.根据权利要求6所述的一种含植物干细胞因子的抑菌组合物的制备方法,其特征在于:所述抑菌组合物的制备方法S5、S6和S8步骤中:所述抗菌剂的总质量百分比为0.1%至10%;所述正电荷化的植物提取物/衍生物的浓度范围为0.0001mg / ml-100mg / ml,所述辅助材料的总质量百分比为90%至99.9%。
9.根据权利要求6所述的一种含植物干细胞因子的抑菌组合物的制备方法,其特征在于:所述抑菌组合物的制备方法S5和S7步骤中混合的抗菌剂、天然保湿剂和生物活性物质的配比比例为3:1:1。
10.根据权利要求7所述的一种含植物干细胞因子的抑菌组合物的制备方法,其特征在于:所述抑菌组合物的制备方法S8步骤中含植物干细胞因子的抑菌组合物可制成0.1克至10克的口服药物、0.5克至5克的外用药物、0.05克至1克的注射剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310535092.2A CN116549612A (zh) | 2023-05-12 | 2023-05-12 | 一种含植物干细胞因子的抑菌组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310535092.2A CN116549612A (zh) | 2023-05-12 | 2023-05-12 | 一种含植物干细胞因子的抑菌组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116549612A true CN116549612A (zh) | 2023-08-08 |
Family
ID=87485689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310535092.2A Pending CN116549612A (zh) | 2023-05-12 | 2023-05-12 | 一种含植物干细胞因子的抑菌组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116549612A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117100679A (zh) * | 2023-10-07 | 2023-11-24 | 佰东靶向(深圳)生物科技有限公司 | 一种植物干细胞因子及其制备方法和应用 |
-
2023
- 2023-05-12 CN CN202310535092.2A patent/CN116549612A/zh active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117100679A (zh) * | 2023-10-07 | 2023-11-24 | 佰东靶向(深圳)生物科技有限公司 | 一种植物干细胞因子及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103110868B (zh) | 一种皮肤护理液及其制备方法 | |
CN108785200B (zh) | 一种抗菌、祛痘、抗皱的银离子保湿面膜液、面膜及其制备方法 | |
CN111744054B (zh) | 一种抗菌促愈合创面敷料及其制备方法 | |
CN116549612A (zh) | 一种含植物干细胞因子的抑菌组合物及其制备方法 | |
CN110693997A (zh) | 一种烫伤烧伤祛腐生肌制剂及制备方法 | |
CN102813751A (zh) | 伤口处理剂 | |
CN111202770A (zh) | 抗菌中草药复方制剂和制备方法及洗手液 | |
CN108066224B (zh) | 一种安胃疡牙膏及其制备方法 | |
CN107913234B (zh) | 一种鹿茸草牙膏及其制备方法 | |
CN110960583A (zh) | 治疗痤疮的药物组合物及其应用 | |
CN115300436A (zh) | 一种抑菌护肤功能的白及组合物及其制备方法 | |
CN103610841A (zh) | 一种治疗竹鼠口腔炎的方法 | |
CN103446564B (zh) | 一种抗菌消炎的中药组合物及其制备方法 | |
CN1246001C (zh) | 治疗妇***道炎疾病的中药制剂及其制备方法 | |
CN112168931B (zh) | 一种治疗口腔溃疡的药物组合物及其制备方法 | |
CN112089802A (zh) | 一种针对肿瘤期免疫低下的中药配方及制备方法 | |
CN103599205B (zh) | 防治伤口感染的中药药液及其制备方法 | |
CN102940776B (zh) | 一种用于防治猪呼吸道疾病的复方青天葵颗粒剂及其制备方法和应用 | |
CN115414295B (zh) | 一种复方植物祛痘抑螨组合物及其制备方法和应用 | |
CN113663049B (zh) | 一种黎药产后药浴泡腾颗粒及其制备方法 | |
CN1094291A (zh) | 鱼腥草口服液 | |
CN110251564B (zh) | 一种治疗痛风关节炎的外用药及其制备方法 | |
CN107397858B (zh) | 一种治疗皮肤病的外用药及制备方法 | |
CN1352971A (zh) | 湿疹消片 | |
CN105560633B (zh) | 两消三止口疮散 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |